Videos

Standardized screening is used by support staff to assess developmental milestones to assist in the recognition of spinal muscular atrophy (SMA).  

Screening of newborns for spinal muscular atrophy (SMA) has been implemented in 33 states. The signs and symptoms leading a pediatrician to a diagnosis of SMA are discussed.

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the challenges and unmet needs psychiatrists and their teams face when treating patients with schizophrenia and their multiple comorbidities.

Joe Avelino, RN, BSN, MHSA, CPHQ, and Henry Nasrallah, MD, review schizophrenia and the needs of these patients.

Valerie Callender, MD, gives an overview of her practice and discusses the challenges during the COVID-19 pandemic.

Jeffrey Bratberg, PharmD, FAPhA, leads discussion tackling common opioid-related misconceptions as well as unintended consequences of the opioid crisis.

Jeremy Adler, DMSc, PA-C, DFAAPA, leads discussion on elements that negatively impacts the quality of care for patients requiring pain management.

Jeffrey Bienstock, MD, FAAP, identifies the various triggers causing flare-ups for atopic dermatitis in patients.

Rakesh Jain, MD, MPH, comments on factors pre-disposing children and adults to ADHD and the impact of disease on patients’ and caregivers’ quality of life (QoL).

Garey H. Noritz, MDwalks us through a virtual pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Diana Castro, MD walks us through a pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Experts discuss opioid crisis complexities, such as the able to manage pain appropriately and the impact of social and structural determinates of health.

From interpreting currently-understood risks to managing isolation-induced indoor allergen exposure, asthmatics may have concerns they address with clinicians.

Surveyed patients discharged from the hospital are reporting respiratory burdens beyond 6 months. Are outpatient facilities equipped to manage COVID-19 long haulers?

A review of 3 new studies, which indicate the association between severe COVID-19 and the chronic disease is more intricate than previously thought.

How dupilumab is observed to benefit EoE patients—and who may administer the biologic therapy.

An interview on the TSLP inhibitor's effect on exacerbations, hospitalizations, and disease progress over 52-week findings.

Perspective on how the interleukin-targeting biologic has unique benefit for the rare, under-resourced disease.